Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 4, July-August, p. 479–484

Publication type: review article

Language: English

Jak3 – Its Significance in Inflammatory Diseases of Joints – New Perspectives for Therapy

Jak3 – znaczenie w zapalnych chorobach stawów – nowe perspektywy terapii

Joanna Krywejko1,, Ewa Morgiel2,, Piotr Wiland3,

1 Department of Family Medicine Silesian Piasts University of Medicine in Wrocław, Poland

2 Department of Rheumatology and Internal Diseases Silesian Piasts University of Medicine, Wrocław, Poland

3 Department of Balneology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Jak3 is a cytoplasmic tyrosine kinase and its expression is limited to cells of immune system. This enzyme takes part in the signal transduction cascade of numerous growth factors, that are crucial for lymphocyte activations and play important roles in lymphocyte differentiation and proliferation. Based on its limited tissue distribution and the evidence if its role in immune cell functioning, Jak3 may represent an attractive target for immunosuppression and inhibitors of Jak3 seems to be important in the treatment of autoimmune diseases and in the prevention of transplant rejection.

Streszczenie

Jak3 jest wewnątrzcytoplazmatyczną kinazą tyrozynową, której ekspresja jest ograniczona do komórek układu immunologicznego. Enzym ten jest składnikiem układu przekazywania sygnału wielu czynników wzrostu, które mają decydujące znaczenie dla aktywacji limfocytów i odgrywają ważną rolę w różnicowaniu i proliferacji tych komórek. Ze względu na ograniczone występowanie w tkankach i znaczącą rolę w funkcjonowaniu komórek układu immunologicznego Jak3 może być atrakcyjnym celem immunosupresji, a inhibitory Jak3 wydają się istotne w leczeniu chorób autoimmunologicznych i w zapobieganiu odrzucania przeszczepów.

Key words

arthritis, autoimmune diseases, Janus kinase, Jak/Stat system, inhibitors of Janus kinase

Słowa kluczowe

zapalenie stawów, choroby autoimmunologiczne, kinaza Janus, układ Jak/Stat, inhibitory kinazy Janus

References (26)

  1. Noguchi M, Yi H, Rosenblatt HM et al.: Interleukin−2 receptor gamma chain mutation results in X−linked severe combined immunodeficiency in humans. Cell 1993, 73,147–157.
  2. Asao H, Okuyama C, Kumaki S et al.: Cutting edge: the common gamma−chain is an indispensable subunit of the IL−21 receptor complex. J Immunol 2001, 167, 1–5.
  3. Pellegrini S, Dusanter−Fourt I: The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem 1997, 248, 615–633.
  4. Gurniak CB, Berg LJ: Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 1996, 87, 3151–3160.
  5. Tortolani PJ, Lal BK, Riva A et al.: Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 1995, 155, 5220–5226.
  6. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D et al.: Expression of Jak3, STAT1, STAT4 and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006, 65, 149–56.
  7. Walker JG, Smith MD: The Jak−STAT pathway in rheumatoid arthritis. J Rheum 2005, 32, 1650–1653.
  8. O’Shea JJ: Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004, 63, Suppl. II, ii67–71.
  9. Ortmann RA, Cheng T, Visconti R et al.: Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res 2000, 2, 16–32.
  10. Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O’Shea JJ et al.: Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003, 23, 147–161.
  11. Musso T, Johnston JA, Linnekin D et al.: Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 1995, 181, 1425–1431.
  12. Macchi P, Villa A, Gillani S et al.: Mutations of Jak−3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377, 65–68.
  13. Russell SM, Tayebi N, Nakajima H et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270, 797–800.
  14. Kile BT, Alexander WS: The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001, 58(11), 1627–1635.
  15. Coonney RN: Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 2002, 17(2), 83–90.
  16. Gad M, Claesson HM, Pedersen AE: Dendritic cells in peripheral tolerance and immunity. APMIS 2003, 111, 766–775.
  17. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392, 245–252.
  18. Adams S, O’Neill DW, Bhardwaj N: Recent advances in dendritic cell biology. J Clin Immunol 2005, 25, 177–188.
  19. Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S: IFN−gamma production by antigen−presenting cells: mechanisms emerge. Trends Immunol 2001, 22, 556–560.
  20. Fukao T, Frucht DM, Yap G, Gadina M, O’Shea JJ, Koyasu S: Inducible expression of STAT4 in dendritic cells and macrophages and its critical role in innate and adaptive immunity. J Immunol 2001, 166, 4446–4455.
  21. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F et al.: BDCA−2, a novel plasmacyotid dendritic cell−specific type II C−type lectin, mediates antigen capture and is a potent inhibitor of interferon−α/ß. J Exp Med 2001, 194, 1823–1834.
  22. Walker J G, Ahern M J, Coleman M et al.: Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66, 992–999.
  23. Lande R, Giacomini E, Serafini B et al.: Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol 2004, 15, 173(4):2815–2824.
  24. Van Kriks CH, Matyszak MK, Gaston JS: Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid. Rheum 2004, 43(4), 453–460.
  25. Changelian PS, Flanagan ME, Ball DJ et al.: Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor. Science 2003, 302, 875–878. doi: 10.1126/science.1087061
  26. Milici AJ, Kudlacz EM et al.: Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008, 10(1), R14.
© Wroclaw Medical University